Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913529
rs121913529
0.060 GeneticVariation BEFREE GTPase-impairing somatic mutations in RAS genes, such as KRAS(G12D), are among the most common oncogenic events in metastatic cancer. 26549032

2016

dbSNP: rs121913529
rs121913529
0.060 GeneticVariation BEFREE Patients with KRAS G12V developed significantly more pleuro-pericardial metastases compared with the remainder of the cohort (94% vs 12%, P<0.0001). 27336603

2016

dbSNP: rs121913529
rs121913529
0.060 GeneticVariation BEFREE Orthotopic implantation of PDCs carrying the activated Kras(G12D)-allele and shRNA against p16(Ink4a) or Trp53 resulted in tumor growth, metastasis, and reduced survival of NSG mice. 25724428

2015

dbSNP: rs121913529
rs121913529
0.060 GeneticVariation BEFREE In summary, by using 'knock-in' mutations of Trp53 we have identified two critical acquired functions of a stably expressed mutant form of p53 that drive PDAC; first, an escape from Kras(G12D)-induced senescence/growth arrest and second, the promotion of metastasis. 20018721

2010

dbSNP: rs121913529
rs121913529
0.060 GeneticVariation BEFREE Thus, a mutation frequency of 40% and a cluster of three mutation types (p.G12D, pG12V, and p.G13D) in primaries and metastases can be defined as benchmarks for routine KRAS analyses. 19679400

2009

dbSNP: rs121913529
rs121913529
0.060 GeneticVariation BEFREE The most common mutation K-Ras(G12V), required for tumor proliferation, survival, and metastasis due to its constitutively active GTPase activity, has provided an ideal target for cancer therapy. 19014906

2009

dbSNP: rs712
rs712
0.040 GeneticVariation BEFREE However, the genotypes <i>TT</i> and <i>GT</i> of rs712 polymorphism in <i>KRAS</i> could contribute significantly to colon localization, node metastasis, poor differentiation and poor chemotherapy response in CRC patients in this sample population. 31156795

2019

dbSNP: rs712
rs712
0.040 GeneticVariation BEFREE Results demonstrated that TT genotype and T allele of rs712 were associated with the increased risk of CRC; the patients with GG genotype and G allele of rs61764370 had a shorter survival and a higher risk of relapse or metastasis of CRC. 26515332

2016

dbSNP: rs712
rs712
0.040 GeneticVariation BEFREE However, the let-7 rs712 G/T polymorphism was discovered to play a potential role in BC tumor metastasis; therefore, it may be employed as a new biomarker or therapy targeted towards resistant tumor metastasis. 26681038

2015

dbSNP: rs712
rs712
0.040 GeneticVariation BEFREE Stratified analyses revealed that CRC patients with the let-7 KRAS rs712 TT genotype were more likely to have clinical stage III or IV disease (OR = 3.29, 95% CI, 1.32-8.20) and distant metastasis (OR = 4.70, 95% CI, 1.81-12.25). 23975373

2014

dbSNP: rs112445441
rs112445441
0.020 GeneticVariation BEFREE Target sequencing analysis revealed, both in primary tumor and metastasis, a pathogenic KRAS gene missense mutation c.38G > A p.(Gly13Asp) and a likely pathogenic CTNNB1 gene missense mutation c.94G > A p.(Asp32Asn). 31823050

2020

dbSNP: rs61764370
rs61764370
0.020 GeneticVariation BEFREE Results demonstrated that TT genotype and T allele of rs712 were associated with the increased risk of CRC; the patients with GG genotype and G allele of rs61764370 had a shorter survival and a higher risk of relapse or metastasis of CRC. 26515332

2016

dbSNP: rs61764370
rs61764370
0.020 GeneticVariation BEFREE The objective of the present study was to explore the molecular mechanism with which a single nucleotide polymorphism (rs61764370) interferes with the interaction between the 3'-untranslated region (3'-UTR) of Kirsten rat sarcoma viral oncogene homolog (KRAS) and let-7a, and its association with the metastasis of osteosarcoma (OS). 27430246

2016

dbSNP: rs112445441
rs112445441
0.020 GeneticVariation BEFREE Thus, a mutation frequency of 40% and a cluster of three mutation types (p.G12D, pG12V, and p.G13D) in primaries and metastases can be defined as benchmarks for routine KRAS analyses. 19679400

2009

dbSNP: rs1137282
rs1137282
0.010 GeneticVariation BEFREE We found rs11246050 in NLRP6 (dominant model, OR/95% CI: 2.028/1.091-3.769, p = 0.025), rs2286742 and rs3740530 in HABP2 (recessive model, OR/95% CI: 9.644/1.307-71.16, p = 0.026 and 3.989/1.413-11.26, p = 0.009), rs2736098 in TERT (recessive model, OR/95% CI: 2.322/1.028-5.242. p = 0.042) and rs62054619 in GAS8-AS1 (recessive model, OR/95% CI: 2.219/1.067-4.617, p = 0.033) were associated with the risk of PTC. rs1137282 in KRAS (dominant model, OR/95% CI: 0.5430/0.3192-0.9236, p = 0.024), rs1347591 and rs4461062 in NUP93 (dominant model, OR/95% CI: 0.6121/0.4128-0.9076, p = 0.015 and 0.6156/0.4157-0.9117, p = 0.015) were associated with low risk of distant metastatic disease in PTC patients. rs33954691 in TERT was associated with the risk of RR-PTC under dominant model (OR/95% CI: 3.161/1.596-6.262). 30826992

2019

dbSNP: rs121913530
rs121913530
0.010 GeneticVariation BEFREE Interestingly, during anti-EGFR treatment, it came to the selection of cells with KRAS G12C mutation which were present from the beginning in the tumor but at a low level (detected by PCR methods) only and led consequently to the metastasis. 23606169

2013

dbSNP: rs121913535
rs121913535
0.010 GeneticVariation BEFREE The HRAS c.37G>C mutation was also found in 8 of 8 associated secondary tumors. 22683711

2012